|
Oral Liquid Topiramate and Zonisamide May Help Solve Compounding Challenges
|
|
It is estimated that there are 3.4 million people, including 3 million adults and 470,000 children, with epilepsy in the United States. The availability of FDA-approved, ready-to-use topiramate oral solution 25 mg/mL and zonisamide oral suspension 100 mg/mL eliminates the need for crushing and compounding these antiseizure molecules. Read more.
|
|
|
GLP-1s Used for Weight Loss Increase Risk of GI Adverse Effects
|
|
|
With the growing popularity of glucagon-like peptide 1 (GLP-1) agonists being used for weight loss, concerns are being raised about the risk of adverse gastrointestinal (GI) effects, including pancreatitis, gastroparesis, and bowel obstruction. Find out what a new study published in in the Journal of the American Medical Association advised about those risks compared with weight loss with bupropion-naltrexone.
|
|
Esketamine Nasal Spray Shows Promise in Treatment-Resistant Depression
|
|
|
Treatment-resistant depression increases the risk of comorbidity, suicide attempts and completions, all-cause mortality, and hospitalization. Could esketamine nasal spray be part of the answer? A new industry-sponsored study published in in the New England Journal of Medicine finds that the efficacy of esketamine nasal spray was superior in achieving remission in a group of patients with the condition. Read more.
|
|
|
Uptick of Adults Planning to Receive New COVID-19 Vaccine
|
|
Pharmacists should expect a moderately high influx of adult patients seeking vaccination against COVID-19 and other seasonal respiratory infections, according to a new Kaiser Family Foundation poll. Uptake is expected to be higher, however, for flu shots and possibly the new respiratory syncytial virus vaccine among those who are eligible. Learn more about the results of this poll.
|
|
